Louis Garguilo

ARTICLES BY LOUIS

  • 5/20/2025

    A Big Pharma professional is battling in the ring of outsourcing ideas, and she’s in the CDMO’s corner. Lynn Cinelli, VP Global Biologics Supply Chain, Bristol Myers Squibb, is fighting against sponsors who don’t recognize inefficiencies and flawed thinking fall hard on their external partners.

  • 5/12/2025

    “We hadn’t built a new site in the U.S. in more than 40 years until the first set of Trump tax cuts, so we need to see those either extended or improved to support this,” Eli Lilly CEO David Ricks recently said, announcing — in Washington, DC — plans to invest $27 billion to build four new manufacturing plants in the U.S.

  • 5/7/2025

    U.S.-based Kailera Therapeutics formation is a revelatory story highlighting the prowess of today’s investor class. All four of its clinical candidates are GLP-1-based therapies. All were in-licensed from China. Kailera's CTO Doug Bakan fills us in on how it came together, and what's next.

  • 5/1/2025

    You might call Anthony Grenier, Sr Director CMC at Reunion Neuroscience, a "phase 2 outsourcing specialist." In his discussion with Chief Editor Louis Garguilo, he describes his experiences, and presents some key factors and advice for biotechs at that middle stage of working with CDMOs.

  • 4/28/2025

    Lynn Cinelli, VP Global Biologics Supply Chain at Bristol Myers Squibb, has been strategizing on why Pharma is so poor at forecasting demand. "The entities that feel the pressures most may be our CDMOs,” she says. She has a better way to go about it — and it starts with the patient.

  • 4/23/2025

    According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will impact your U.S.-based CDMOs.

  • 4/21/2025

    Why did George Hlass found Pharma Expanse, roughly described as a “BD-for-hire organization”? He says it was born of experiences over a long career in the role of business development (BD) professional. In part two, Hlass describes how, since 2023, the demand for this service has taken him by surprise.

  • 4/14/2025

    You want the best shot at a successful CDMO selection, and subsequent relationship – one that thrives during the good times, and survives the stress of development and manufacturing challenges? Your CDMO’s business development (BD) professional is a good place to focus. Here's why.

  • 4/8/2025

    Doom and gloom in the drug development and manufacturing supply chain.  Predictions of disruptions and displacements. The Trump tariff ploy will fail, and costs/prices will skyrocket. But have you considered this “risk”? The tariff tantrum lowers national export/import duties for the entire globe.

  • 4/7/2025

    Biotechs can learn about outsourcing facility selection from a pharma company like Takeda, who evaluates both internal and external locations to place its development and manufacturing projects. This is part two of Chief Editor Louis Garguilo's discussion with Takeda Linz's Roland Fabris.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.